|Bid||36.86 x 800|
|Ask||41.00 x 3000|
|Day's Range||38.12 - 38.71|
|52 Week Range||32.69 - 41.78|
|Beta (3Y Monthly)||0.64|
|PE Ratio (TTM)||39.98|
|Forward Dividend & Yield||1.40 (3.43%)|
|1y Target Est||42.26|
A whopping number of 13F filings filed with U.S. Securities and Exchange Commission has been processed by Insider Monkey so that individual investors can look at the overall hedge fund sentiment towards the stocks included in their watchlists. These freshly-submitted public filings disclose money managers’ equity positions as of the end of the three-month period […]
The $1.4 billion Moderna lost in value is greater than the market value of more than half the companies in the Nasdaq Biotechnology Index. The company boasts partnerships with sector juggernauts including Merck & Co. and AstraZeneca Plc, so its growth prospects have attracted notable attention across the sector.
The results come after AstraZeneca warned last month that its immunotherapy treatment Imfinzi did not meet the main goal of improving survival rates for patients with the most advanced form of lung cancer, putting pressure on its shares. AstraZeneca has been seen as having a head start in the race for cancer treatments, and Imfinzi was aiming to be the new standard of care in treating early inoperable stage III lung cancer.
Inovio (INO) to receive an undeclared milestone amount from AstraZeneca following the initiation of dosing in a phase II combo inspection of the latter's MEDI0457 for treating HPV-related cancers.
Moody's Investors Service has today changed to negative from stable the outlook of GlaxoSmithKline plc (GSK) and its guaranteed subsidiaries. The change in outlook follows the company's 3 December announcement of its intention to acquire Tesaro for $5.1 billion. At the same time, Moody's has affirmed GSK's A2/(P)A2 long-term and (P)Prime-1 ratings.
NEW YORK, NY / ACCESSWIRE / December 5, 2018 / U.S. equities plunged on Tuesday as skepticism over the U.S. and China’s ability to close a trade agreement weighed on the markets. The Dow Jones Industrial ...
, have been warned they face fresh shareholder unrest if they fail to address investor concerns that have already resulted in significant protest votes at their annual meetings. The Investment Association has written to 32 companies that appeared on the UK trade body’s Public Register of shareholder votes for the past two years. The “repeat offenders” landed on the register for the “exact same resolution” in consecutive years, suggesting they had not responded “sufficiently to investor views and in doing so are risking more shareholder dissent”.
TESARO (TSRO) receives an acquisition offer from London-based pharma giant, Glaxo, valuing the company at $75 a share. Total value of the deal stands at $5.1 billion which includes acquisition of debt.
The Moderna IPO is set to become the largest public debut of a venture capital-backed biotech company, after it announced terms that could raise $521 million.
Following the agreement, a prospective lung cancer study with Biocartis's Idylla EGFR Mutation Test will be conducted in Belgium, France, Germany and Italy. "We are very excited to be collaborating with AstraZeneca in the area of lung cancer ... For Biocartis, this is yet another important collaboration to support the further roll-out of our Idylla platform," Biocartis Chief Executive Officer Herman Verrelst said.
Attractive stocks have exceptional fundamentals. In the case of AstraZeneca PLC (LON:AZN), there’s is a company with a an impressive history of dividend payments as well as a excellent future Read More...
PRESS RELEASE : 29 November 2018, 07:00 CET Biocartis and AstraZeneca Enter Into Agreement Aimed at Faster Lung Cancer Biomarker Results Mechelen, Belgium, 29 November 2018 - Biocartis Group NV (the ...
China is approving foreign drugs at a record pace, opening the door to its lucrative market for the world’s leading pharmaceutical companies, while also extracting big discounts. Regulators have greenlighted dozens of outside drugs for use in China over the past 21 months, some within a few weeks. The approvals follow a series of policy moves by China to provide its 1.4 billion people access to new, lifesaving drugs, especially those that treat cancer.
AstraZeneca (AZN) gets Orphan Drug status for Fasenra in the United States for the treatment of eosinophilic granulomatosis with polyangiitis, a rare autoimmune disease.
27 scientific presentations, including long-term data from CALQUENCE in mantle cell lymphoma and updated early-phase trial results in chronic lymphocytic leukemia
FDA grants approval to Pfizer's (PFE) new cancer drug and label expansion of AbbVie/Roche's Venclexta. CHMP gives nod to several drugs
This article is written for those who want to get better at using price to earnings ratios (P/E ratios). To keep it practical, we’ll show how AstraZeneca PLC’s (LON:AZN) P/E Read More...